Lilly Says Foundayo Is Taking Close To 4 In 10 New Oral Obesity Starts, Even As Sales Trail Forecasts
Executives pushed the obesity pill's share and a diabetes decision, while CNBC put its quarterly sales at $184 million.
Foundayo now captures nearly 4 in 10 new prescriptions in oral obesity treatment, Lilly USA head Ilya Yuffa said on Eli Lilly's third-quarter earnings call Thursday. The pill brought in $184 million in the quarter, below analyst forecasts of around $229 million, CNBC reported.
Share gains, with a ceiling on the doses
Yuffa said Lilly is taking 45% of the growth in oral obesity drugs from the second quarter to the third. The number of new Foundayo patients in the third quarter doubled from the prior quarter, Chief Financial Officer Lucas Montarce said.
Answering a question from a Goldman Sachs analyst on dose titration, Yuffa said about 25% of patients are on one of the pill's maintenance doses. He said that is higher than on the rival Wegovy pill. "Of course, that's something to continue to monitor," he added.
Diabetes as the next leg
Montarce said Lilly expects U.S. regulatory action on Foundayo for type 2 diabetes in the fourth quarter. A speaker the transcript tags as a Citi analyst, apparently an executive, said roughly half of U.S. GLP-1 volume is in diabetes and called the opportunity "another leg to the stool." The speaker noted that coverage and reimbursement are still needed.
Eli Lilly, which makes diabetes, obesity, cancer, immune and neurological medicines including Mounjaro and Zepbound, raised its full-year revenue outlook to between $91 billion and $92 billion.
Four markets abroad, 40 more in review
Patrick Johnson, president of Lilly International, said the pill has launched in four countries outside the U.S. and the rollout is in line with expectations. Mexico is slightly above expectations, he said, while the UK launch could not be fully promoted until October because of pre-vetting requirements from the MHRA, the UK medicines regulator.
Montarce said the drug is under regulatory review in more than 40 additional countries, and Lilly still expects a global rollout in all major markets in 2027.
Lilly's investor day, focused on research and pipeline, is set for December 7.
Sources
- Eli Lilly (LLY) earnings Q3 2026 — CNBC
- Eli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales — Yahoo Finance
- Eli Lilly Lifts Revenue Outlook on Weight-Loss Drug Sales, Trims Profit View on Deal Charges — Reuters
- Eli Lilly lifts sales outlook as blockbuster weight-loss drugs fuel growth (LLY:NYSE) | Seeking Alpha — seekingalpha.com
- Eli Lilly raised its outlook a third time in Q3 2026 earnings — qz.com